Company Overview

Update
Status:
Acquired (Separate Entity) by Teva Pharmaceutical Industries
Funding:
$45.6M
Categories:
Biotechnology
Description:
Labrys Biologics develops treatments for chronic migraine.

Detailed Description

Update

Labrys Biologics Inc., a company focused on treatments for chronic migraine.

Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.

RN-307 was originally developed by Rinat Pharmaceuticals, acquired by Pfizer in 2006.

Current Team (1)

Update

Funding Rounds (2) - $45.6M

Update

Board Members and Advisors (1)

Update

Investors (4)

Update
  • Bb3d6fbd0e442789b59061f392f8ad0d

    InterWest Partners

    InterWest invests an average of about $7 - 15 million over the span of their involvement with...
  • 773c0a0237bbae3861ec60373fb7001a

    Canaan Partners

    IT and Healthcare VC
  • A72157320397be4c637c4da2b885a5f8

    Sofinnova Ventures

    Since 1974, Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build...
  • 329bbe14e128aed075b82f86a6e41b4e

    venBio

    venBio LLC is a private equity and venture capital firm specializing in investments in early...